What do systematic reviews say?

Bisphosphonates vs no bisphosphonates

• Bisphosphonates for osteoporosis in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  12 participants
  GRADE not reported

Bisphosphonates vs placebo

• Bisphosphonates for osteoporosis in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 113 participants
  Low

Bisphosphonates vs another bisphosphonate

It is very uncertain whether bisphosphonates changes adverse events compared with another bisphosphonate (very low certainty).

• Bisphosphonates for osteoporosis in primary biliary cirrhosis 2011 · Cochrane Headline outcomes only
  RR 0.95 [0.31, 2.94]
  2 studies · 62 participants
  Very low

Bisphosphonates vs placebo or no intervention

It is very uncertain whether bisphosphonates changes adverse events compared with placebo or no intervention (very low certainty).

• Bisphosphonates for osteoporosis in primary biliary cirrhosis 2011 · Cochrane Headline outcomes only
  RR 1 [0.49, 2.04]
  2 studies · 46 participants
  Very low

Bisphosphonates vs placebo/no treatment

Bisphosphonates probably leads to higher adverse events: renal compared with placebo/no treatment (moderate certainty).

• Bisphosphonates for advanced prostate cancer 2017 · Cochrane Headline outcomes only
  RR 1.65 [1.11, 2.46]
  7 studies · 1794 participants
  Moderate

Bisphosphonates vs placebo/no treatment

Bisphosphonates showed no clear difference in adverse events: nausea compared with placebo/no treatment (moderate certainty).

• Bisphosphonates for advanced prostate cancer 2017 · Cochrane Headline outcomes only
  RR 1.19 [1, 1.41]
  9 studies · 3008 participants
  Moderate

Bisphosphonates vs control

Bisphosphonates showed no clear difference in serious adverse events compared with control (low certainty).

• Bisphosphonates for steroid‐induced osteoporosis 2016 · Cochrane Headline outcomes only
  RR 0.91 [0.74, 1.12]
  15 studies · 1703 participants
  Low

Bisphosphonates vs control

Bisphosphonates showed no clear difference in withdrawals due to adverse events compared with control (low certainty).

• Bisphosphonates for steroid‐induced osteoporosis 2016 · Cochrane Headline outcomes only
  RR 1.06 [0.77, 1.47]
  15 studies · 1790 participants
  Low

Bisphosphonates vs placebo/no treatment

It is very uncertain whether bisphosphonates changes adverse events: osteonecrosis of the jaw compared with placebo/no treatment (very low certainty).

• Bisphosphonates for advanced prostate cancer 2017 · Cochrane Headline outcomes only
  RR 1.92 [0.75, 4.9]
  5 studies · 1626 participants
  Very low

Bisphosphonates vs placebo

Bisphosphonates showed no clear difference in number of participants who withdrew due to adverse events compared with placebo (low certainty).

• Bisphosphonates for Paget's disease of bone in adults 2017 · Cochrane Headline outcomes only
  RR 1.01 [0.41, 2.52]
  6 studies · 517 participants
  Low

Bisphosphonates vs control

• Bisphosphonates for osteoporosis in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 206 participants
  Moderate

Zoledronate vs pamidronate or risedronate

It is very uncertain whether zoledronate changes number of participants who withdrew due to adverse events… compared with pamidronate or risedronate (very low certainty).

• Bisphosphonates for Paget's disease of bone in adults 2017 · Cochrane Headline outcomes only
  RR 2.04 [0.43, 9.59]
  2 studies · 437 participants
  Very low